Navigation Links
InVitria Successfully Completes Beta Testing and Announces Commercial Launch of Optiferrin for Mammalian Cell Culture
Date:9/17/2009


Optiferrin shown to provide superior performance in cell culture and addresses the need for animal-free transferrin in many applications including Stem Cells, Primary Cells, Hybridoma Cells and Chinese Hamster Ovary (CHO) cells.

Fort Collins, CO September 17, 2009 / b3c newswire / C InVitria today announced the launch of Optiferrin, a high performance, well-defined and animal-free recombinant transferrin for use in mammalian cell culture. Optiferrin is a cell culture supplement which supports cell growth by regulating the amount of iron transported to the cell. Since iron is required for healthy cell culture performance, it is a critical component to reach optimal performance.

Optiferrin has undergone extensive testing by our beta customers since June 2009. They have formulated Optiferrin into their cell culture media to provide maximum performance and they liked their results. We are delighted to be able to bring this sort of value to our customers through innovations like Optiferrin, said Scott Deeter, President & CEO of InVitria.

Transferrin is natures way to deliver iron in a non-toxic manner, said Dr. Steve Pettit, InVitrias Director of Cell Culture Development. Our product development, along with beta customer results, confirmed that Optiferrin delivered optimal performance without any cell damage. This alleviates customers concerns about animal-origin infectious contaminants or the headaches caused by addition of elemental iron and iron chelators in cell culture media, said Dr. Pettit.

Optiferrin is a complimentary product to InVitrias other cell culture supplement products, which include Cellastim, Lacromin, Zap-CHO and Zap-Hybridoma.



About InVitria - www.InVitria.com
InVitria develops, manufactures and markets a portfolio of high performance and well defined cell culture media components and reagents used in bioprocessing, biopharmaceutical formulation, stem cell & regenerative medicine, life science research, medical devices and diagnostics.

For more information about InVitrias product line, contact us at info@InVitria.com or call 1-800-916-8311.


'/>"/>
b3c newswire

Related biology news :

1. InVitria Sponsors ESACT 2009 in Dublin, Ireland
2. InVitria to Unveil Powerful Cell Culture Media Component ZAP-CHO
3. InVitria Announces Launch of Recombinant Albumin for Diagnostics
4. UOG scientists successfully compete for research grants
5. McGill/JGH researchers successfully reverse multiple sclerosis in animals
6. Funxional successfully completes initial clinical trial of FX125L, an anti-inflammatory drug with a novel mechanism of action
7. In troubled economic times, BioSquare 2009 successfully serves as business and innovation starter
8. Salk researchers successfully reprogram keratinocytes attached to a single hair
9. Model successfully predicts large river system fish diversity
10. Scientists successfully treat new mouse model of inflammatory bowel disease
11. Researchers successfully simulate photosynthesis and design a better leaf
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/5/2017)... KEY FINDINGS The global market ... CAGR of 25.76% during the forecast period of 2017-2025. ... for the growth of the stem cell market. ... MARKET INSIGHTS The global stem cell market is segmented ... The stem cell market of the product is segmented ...
(Date:3/30/2017)... HONG KONG , March 30, 2017 ... developed a system for three-dimensional (3D) fingerprint identification by adopting ground ... technology into a new realm of speed and accuracy for use ... applications at an affordable cost. ... ...
(Date:3/27/2017)... , March 27, 2017  Catholic Health ... and Management Systems Society (HIMSS) Analytics for achieving ... Adoption Model sm . In addition, CHS previously ... U.S. hospitals using an electronic medical record (EMR). ... its high level of EMR usage in an ...
Breaking Biology News(10 mins):
(Date:7/17/2017)... ... July 17, 2017 , ... ... by a wide range of overlapping clinical features. The advancement of targeted next-generation ... field of NDD research and testing. , However, designing a custom panel ...
(Date:7/17/2017)... ... July 17, 2017 , ... DuPont ... strategy. A website (openinnovation.pioneer.com) dedicated to connecting third-party innovators with DuPont ... discovery, plant breeding, enabling technologies, biologicals and digital solutions. , “DuPont Pioneer is ...
(Date:7/15/2017)... (PRWEB) , ... July 15, 2017 , ... Cuvette ... 5 years. During this time, the people at FFS have learned that their ... customers, engineers at FFS are able to launch new products to meet the changing ...
(Date:7/14/2017)... ... July 13, 2017 , ... ... calibration verification test kit has received US FDA 510 (k) clearance for use ... plasma matrix, evaluates D-Dimer. Each VALIDATE® D-Dimer kit, prepared using the CLSI EP06-A ...
Breaking Biology Technology: